Sep 30 2024 32 mins 4
In this episode, listen to Matthew S. Davids, MD, MMSc, and Lindsey Roeker, MD, discuss BTK inhibitor resistance and how it shapes treatment choices for patients with CLL, including:
- Contemporary treatment paradigms for patients with CLL
- Safety and efficacy of current regimens
- Molecular testing, including when and how to test for BTK inhibitor resistance
- Considering BTK inhibitor resistance when sequencing therapy
Program faculty:
Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Leader, Lymphoma Program
Dana-Farber/Harvard Cancer Center
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts
Lindsey Roeker, MD
Assistant Attending
CLL Program Director
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Resources:
To review a CME-certified text activity and download slides associated with this podcast discussion, please visit the program page.
